A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

We evaluated the safety and biologic activity of the BH3 mimetic protein, navitoclax, combined with rituximab, in comparison to rituximab alone. One hundred and eighteen patients with chronic lymphocytic leukemia (CLL) were randomized to receive eight weekly doses of rituximab (arm A), eight weekly...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Leuk Lymphoma
Glavni autori: Kipps, Thomas J., Eradat, Herbert, Grosicki, Sebastian, Catalano, John, Cosolo, Walter, Dyagil, Iryna S., Yalamanchili, Sreeni, Chai, Akiko, Sahasranaman, Srikumar, Punnoose, Elizabeth, Hurst, Deborah, Pylypenko, Halyna
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4643417/
https://ncbi.nlm.nih.gov/pubmed/25797560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1030638
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items